ECSP21021189A - Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso - Google Patents

Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso

Info

Publication number
ECSP21021189A
ECSP21021189A ECSENADI202121189A ECDI202121189A ECSP21021189A EC SP21021189 A ECSP21021189 A EC SP21021189A EC SENADI202121189 A ECSENADI202121189 A EC SENADI202121189A EC DI202121189 A ECDI202121189 A EC DI202121189A EC SP21021189 A ECSP21021189 A EC SP21021189A
Authority
EC
Ecuador
Prior art keywords
vitamin
methods
dosage forms
preparation
pediatric dosage
Prior art date
Application number
ECSENADI202121189A
Other languages
English (en)
Inventor
Ken O'shea
Stephen James Quinlan
Reem Elamein Elsiddig
Marta Golec
James Joseph Mcdonald
Praful Balavant Deshpande
John Gerard O'brien
Original Assignee
Opko Ireland Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68165642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21021189(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Ireland Global Holdings Ltd filed Critical Opko Ireland Global Holdings Ltd
Publication of ECSP21021189A publication Critical patent/ECSP21021189A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación pediátricas y de liberación modificada de compuestos de vitamina D, y métodos de elaboración y uso de las mismas.
ECSENADI202121189A 2018-08-31 2021-03-26 Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso ECSP21021189A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862725940P 2018-08-31 2018-08-31

Publications (1)

Publication Number Publication Date
ECSP21021189A true ECSP21021189A (es) 2021-04-29

Family

ID=68165642

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202121189A ECSP21021189A (es) 2018-08-31 2021-03-26 Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso

Country Status (22)

Country Link
US (4) US11000480B2 (es)
EP (1) EP3843706A1 (es)
JP (2) JP7603000B2 (es)
KR (1) KR20210054539A (es)
CN (2) CN112912067B (es)
AU (4) AU2019329905B2 (es)
BR (1) BR112021003788A2 (es)
CA (1) CA3110020A1 (es)
CL (2) CL2021000493A1 (es)
CO (1) CO2021003805A2 (es)
CR (2) CR20210158A (es)
DE (1) DE202019005769U1 (es)
EA (1) EA202190633A1 (es)
EC (1) ECSP21021189A (es)
IL (2) IL280937B2 (es)
MX (1) MX2020011740A (es)
MY (1) MY210476A (es)
PE (1) PE20211489A1 (es)
PH (1) PH12021550413A1 (es)
SG (1) SG11202101905YA (es)
TW (1) TWI856972B (es)
WO (1) WO2020044314A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法
US20210308151A1 (en) 2020-04-06 2021-10-07 Eirgen Pharma Ltd. Activating endogenous antimicrobials to treat sars-cov-2 infection
CN120694962A (zh) 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途
WO2022103639A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114176164A (zh) * 2021-12-17 2022-03-15 广东驱动力生物科技股份有限公司 反刍动物用水溶性抗应激助剂
CN116426595A (zh) * 2023-04-10 2023-07-14 北京泛球生物科技有限公司 一种利用固定化羟化酶转化制备25-羟基维生素d3的方法
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
DE69214704T2 (de) * 1991-04-09 1997-04-17 Takeda Chemical Industries Ltd Stabilisiertes Vitamin D Arzneimittel
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
JP3722832B2 (ja) * 1992-06-22 2005-11-30 ルーナー、コーポレーション 経口用１α−ヒドロキシプレビタミンＤ
US8980334B2 (en) * 2001-02-28 2015-03-17 Axiomedic Ltd. Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
ES2593047T3 (es) * 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ATE476176T1 (de) * 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
JP5518302B2 (ja) 2008-05-16 2014-06-11 一丸ファルコス株式会社 ポリマーミセルからの疎水性物質の徐放方法
CN101584683A (zh) * 2009-06-12 2009-11-25 沈阳药科大学 美托拉宗缓释胶囊及其制备方法
US9649311B2 (en) * 2009-10-26 2017-05-16 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
JP5546948B2 (ja) 2010-05-14 2014-07-09 理研ビタミン株式会社 多芯型マイクロカプセル
WO2012047098A1 (en) * 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
WO2013105026A1 (en) * 2012-01-09 2013-07-18 Department Of Biotechnology (Dbt) A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins
AU2013229990B2 (en) 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20160008377A1 (en) * 2014-07-12 2016-01-14 Aphios Corporation Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases
JP2017523220A (ja) 2014-08-07 2017-08-17 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
BR112018006720B1 (pt) 2015-10-07 2023-05-02 Dsm Ip Assets B.V Extrusados multivitamínicos, alimento, ração, formulações para cuidado pessoal e/ou farmacológicas ou pré-misturas dos mesmos
JP7032322B2 (ja) * 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
CN108420797B (zh) 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法

Also Published As

Publication number Publication date
IL280937A (en) 2021-04-29
MX2020011740A (es) 2021-04-19
CR20250081A (es) 2025-05-05
EA202190633A1 (ru) 2021-07-12
AU2019329905B2 (en) 2024-02-01
PE20211489A1 (es) 2021-08-11
BR112021003788A2 (pt) 2021-06-08
US20220000783A1 (en) 2022-01-06
AU2021107168A4 (en) 2021-12-09
US12433842B2 (en) 2025-10-07
CL2021000493A1 (es) 2021-07-23
CL2023002539A1 (es) 2024-02-23
IL322133A (en) 2025-09-01
JP2025060651A (ja) 2025-04-10
EP3843706A1 (en) 2021-07-07
AU2021107174A4 (en) 2021-12-09
CN120154576A (zh) 2025-06-17
CO2021003805A2 (es) 2021-04-19
KR20210054539A (ko) 2021-05-13
US20200338006A1 (en) 2020-10-29
US11000480B2 (en) 2021-05-11
WO2020044314A1 (en) 2020-03-05
IL280937B2 (en) 2025-12-01
US12133917B2 (en) 2024-11-05
CN112912067A (zh) 2021-06-04
US20250025423A1 (en) 2025-01-23
CN112912067B (zh) 2025-04-04
TW202034905A (zh) 2020-10-01
CA3110020A1 (en) 2020-03-05
DE202019005769U1 (de) 2022-01-13
JP7603000B2 (ja) 2024-12-19
CR20210158A (es) 2021-05-21
SG11202101905YA (en) 2021-03-30
PH12021550413A1 (en) 2021-09-27
IL280937B1 (en) 2025-08-01
AU2019329905A1 (en) 2021-03-18
JP2021535155A (ja) 2021-12-16
TWI856972B (zh) 2024-10-01
MY210476A (en) 2025-09-24
AU2024202877A1 (en) 2024-05-23
US20210401752A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
MX392916B (es) Estructuras de nanofibra y métodos de uso de las mismas
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX2018014154A (es) Polinucleotidos moduladores.
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
ECSP18049762A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
IL280809B (en) Novel compositions, their use, and methods for their formation
MX2021016050A (es) Formulaciones transdermicas.
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
CL2021003498A1 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
BR112019003987A2 (pt) formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения